NCT00424814View on ClinicalTrials.gov

Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

November 30, 2012

Conditions
HIV Infections
Interventions
DRUG

Kaletra (lopinavir/ritonavir)

(200/50 mg x2)x 2/d= 2 pills twice daily

DRUG

Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)

Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily

Trial Locations (1)

75013

Hopital Pitie salpetriere, Paris

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT00424814 - Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva | Biotech Hunter | Biotech Hunter